Is There a Preferred β-Lactam/β-Lactamase Inhibitor Agent for Treatment of KPC-Producing Enterobacterales Infection?February 22nd 2023
Carbapenem-resistant Enterobacterales present considerable treatment challenges. Recent cumulative evidence supports preference for therapies.
Restoring Hope by Restoring Gut Flora: Rebyota and the Future of Combating Recurrent CDIFebruary 18th 2023
Although fecal microbiota, live-jslm (Rebyota; RBX2660) is the first fecal microbiota product approved by the FDA, there are other microbiota-based agents in the pipeline.
Linezolid Coadministration With Medications for Opioid Use Disorder: A Serotonin Toxicity Tightrope?February 16th 2023
This study characterized the incidence of serotonin syndrome and identified contributing risk factors with combined medications for opioid use disorder (MOUD) and linezolid use.